Levetiracetam Ibigen

Levetiracetam, the active ingredient in Levetiracetam Ibigen, is an anticonvulsant presented as an intravenous solution for injection use. It is indicated for the treatment of partial seizures, with or without secondary generalisation, and for generalized tonic‑clonic seizures in patients diagnosed with epilepsy.

GNH USA supplies Levetiracetam Ibigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to essential antiepileptic medicines across the EU and other regulated markets.

Levetiracetam is an antiepileptic medication used to control seizure activity in epilepsy.

- Partial seizures: reduces the frequency and severity of focal seizures. - Generalized tonic‑clonic seizures: prevents occurrence of bilateral convulsive episodes. - Secondary generalised seizures: controls spread of focal seizures to a generalized pattern.

Levetiracetam is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Somnolence: increased sleepiness or fatigue. - Headache: mild to moderate cranial pain. - Irritability: mood changes or agitation. - Nausea: occasional gastrointestinal upset. - Fatigue: reduced energy levels.

Serious or Rare Side Effects: - Severe allergic reactions: rash, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: rare but serious skin eruption. - Blood dyscrasias: neutropenia or thrombocytopenia. - Suicidal ideation: emergence of depressive thoughts. - Severe depression: marked mood disturbances. - Rash: extensive or bullous skin lesions.

Levetiracetam should be used with attention to patient‑specific factors and proper handling.

- Renal impairment: assess renal function and adjust dosing as needed. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Pregnancy: safety category unknown; weigh potential benefits against risks. - Concomitant CNS depressants: observe for enhanced sedation or respiratory depression. - Behavioral changes: monitor for agitation, aggression, or mood swings. - Store at below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Levetiracetam may interact with other medicines, requiring vigilance.

Major Interactions (Avoid): - Carbamazepine: may lower levetiracetam plasma concentrations. - Phenytoin: can reduce levetiracetam levels, diminishing efficacy. - Phenobarbital: may decrease levetiracetam exposure.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): increased sedation risk. - Alcohol: additive central nervous system depression. - Valproic acid: may raise levetiracetam levels, requiring observation.